51ÊÓƵ

There’s a lot of drama here, as business stories go. Is the company going to be definitively exposed as the Enron of biotech startups? Or will it be vindicated as a misunderstood and unfairly persecuted innovator that, well, made a few mistakes. If the former, you get the sense only a talent on a par with David Simon‘s could coherently dramatize the shortcomings of the multiple institutions implicated in this mess. The story is compelling even without the appearance to date of the most important characters — real-life patients who may have been harmed by Theranos’ faulty blood tests. (Brooks, 5/23)